Pomp Investments investor Anthony Pompliano discusses the likelihood of a Bitcoin boom on 'The Claman Countdown.' The ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

Notably, the eczema and asthma treatment from Sanofi and Regeneron nearly doubled the national TV ad spend of Vicks, ...

Neuland Labs share price surged after AbbVie’s emraclidine trial setback shifted focus to KarXT. As the exclusive Xanomaline ...

JS and TV are supported by a senior clinical researcher fellowship from the Research Foundation Flanders (FWO). Competing ...

Asian stocks fell on Monday, led by a more than 2% drop in Hong Kong’s Hang Seng index, as China’s stimulus package ...

U.S. equities continued their post-election rally at midday, fueled by optimism that the new Trump administration will be a ...

You can be a little greedy sometimes and find great stocks that possess solid growth prospects and also pay dividends.

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma stocks. Healthcare takes the concept of ‘defensive’ further than almost any ...

Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...